EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING

EHA Library, Subbaiah Chary Nimmagadda, 385455

CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

EHA Library, Michael Gulrajani, 385456

SPLENOMEGALY DEVELOPMENT PRECEDES THE PROGRESS OF HEMATOPOIETIC STEM CELLS MIGRATION TO SPLEEN IN MURINE MYELOFIBROSIS MODELS

EHA Library, Takaaki Maekawa, 385457

THE TELOMERASE INHIBITOR IMETELSTAT DIFFERENTIALLY TARGETS JAK2V617F- VERSUS CALR-MUTANT MYELOPROLIFERATIVE NEOPLASM CELLS AND INHIBITS JAK-STAT SIGNALING

EHA Library, Nicolas Chatain, 385458

SKLB054, A NOVEL JAK2 INHIBITOR, POTENTLY TREATS MYELOPROLIFERATIVE NEOPLASM WITH JAK2V617F MUTATION

EHA Library, Ailin Zhao, 385459

TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)

EHA Library, Michael Loschi, 385488

LOW DOSE CYTARABINE FOR ADULT PATIENTS WITH NEWLY DIAGNOSED LANGERHANS CELL HISTIOCYTOSIS: A SINGLE ARM, SINGLE CENTER, PROSPECTIVE PHASE 2 STUDY

EHA Library, Long Chang, 385489

FACTORS ASSOCIATED WITH THROMBOSIS IN MYELOFIBROSIS

EHA Library, Gopila Gupta, 385490

LEUKOCYTOSIS SELECTS A SUBGROUP OF LOW-RISK PV PATIENTS IN WHOM PHLEBOTOMY-ALONE MAY BE INSUFFICIENT

EHA Library, Tiziano Barbui, 385491

COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY

EHA Library, Sung-Eun Lee, 385492

EFFICACY AND SAFETY OF TRAMETINIB IN ADULTS WITH LANGERHANS CELL HISTIOCYTOSIS AND ERDHEIM-CHESTER DISEASE

EHA Library, Vitalii Latyshev, 385493

REDUCTION IN RED BLOOD CELL TRANSFUSION BURDEN: A NOVEL LONGITUDINAL TIME-DEPENDENT ANALYSIS IN PATIENTS WITH TRANSFUSION-DEPENDENT MYELOFIBROSIS TREATED WITH MOMELOTINIB

EHA Library, Claire Harrison, 385494

DISEASE PROGRESSION AND LEUKEMIC TRANSFORMATION IN PATIENTS WITH LOWER-RISK MYELOFIBROSIS: AN ANALYSIS FROM MOST

EHA Library, Rami S. Komrokji, 385495

TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS

EHA Library, Elisa Rumi, 385496

AIPSS-MF MACHINE LEARNING MODEL AS USEFUL PROGNOSTIC SCORE COMPARED TO IPSS IN THE SETTING OF MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Andrea Duminuco, 385497

PHARMACOKINETIC AND PHARMACODYNAMIC EFFECTS OF RUSFERTIDE IN POLYCYTHEMIA VERA:  RESULTS FROM AN ONGOING PHASE 2 STUDY IN PATIENTS WITH ELEVATED HEMATOCRIT VALUES

EHA Library, Marina Kremyanskaya, 385498

CHARACTERISTICS AND OUTCOMES OF CARDIOVASCULAR INVOLVEMENT IN ERDHEIM-CHESTER DISEASE

EHA Library, Reema Tawfiq, 385499

NEXT GENERATION SEQUECING CONTRIBUTES TO DEFINE PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASM CLINICAL PHENOTYPE

EHA Library, ALDO LEONE, 385500

CLINICAL CHARACTERISTICS OF PULMONARY EMBOLISM IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Ivan Krecak, 385501

A REAL-WORLD STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Minghui Duan, 385502

NEUTROPHIL-TO-LYMPHOCYTE AND PLATELET-TO-LYMPHOCYTE RATIO AS NOVEL PROGNOSTIC BIOMARKES IN BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Mirjana Cvetkovic, 385503

CLINICAL CHARACTERISTICS AND OUTCOMES IN 175 PATIENTS WITH MYELOFIBROSIS ACCORDING TO GENOMIC CLASSIFICATION USING NEXT-GENERATION SEQUENCING

EHA Library, Marta Garrote Ordeig, 385504

BROMODOMAIN AND EXTRA-TERMINAL (BET) INHIBITOR INCB057643 (LIMBER-103) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MYELOFIBROSIS (R/R MF) AND OTHER ADVANCED MYELOID NEOPLASMS: A PHASE 1 STUDY

EHA Library, Prithviraj Bose, 385505

NEXT GENERATION SEQUENCING IDENTIFIES SUBGROUPS OF PATIENTS WITH TRIPLE NEGATIVE/ PRIMARY THROMBOCYTOSIS WITH DIFFERENT CLINICAL OUTCOMES

EHA Library, VALENTINA SANGIORGIO, 385506

INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Lucia Masarova, 385507

CHILDHOOD-ONSET ERDHEIM-CHESTER DISEASE IN THE MOLECULAR ERA: CLINICAL PHENOTYPE AND LONG-TERM OUTCOME OF 21 PATIENTS

EHA Library, Francesco Pegoraro, 385508

REAL-WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION IN MYELOFIBROSIS PATIENTS WITH ANEMIA

EHA Library, John Mascarenhas, 385509

THE IMPACT OF POLYCYTHEMIA VERA ON DAILY LIVING, AND SYMPTOM AND TREATMENT PERCEPTION GAPS BETWEEN PATIENTS AND PHYSICIANS: RESULTS OF A CROSS-SECTIONAL SURVEY IN JAPAN

EHA Library, Yuka Sugimoto, 385510

CLINICAL FEATURES OF PHILADELPHIA-NEGATIVE MPN DEVELOPED IN ADOLESCENTS AND YOUNG ADULTS IN JAPAN

EHA Library, Yuka Sugimoto, 385511

A SINGLE CENTER EXPERIENCE OF DIAGNOSTICS AND TREATMENT OF RARE MYELOID/LYMPHOID NEOPLASMS WITH PDGFRB GENE REARRANGEMENT

EHA Library, Irina Nemchenko, 385513

BRENTUXIMAB VEDOTIN, NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE FOR ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA: UPDATED EFFICACY AND SAFETY RESULTS FROM THE SINGLE ARM PHASE 2 STUDY

EHA Library, Chris Yasenchak, 385514

UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ANTI–PD-1–NAIVE RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Peter Borchmann, 385515

PEMBROLIZUMAB MONOTHERAPY AS A FIRST THERAPY FOR HODGKIN LYMPHOMA IS DELIVERABLE IN OLDER OR ABVD  INELIGIBLE PATIENTS, DOES NOT PRECLUDE SUBSEQUENT THERAPY, AND PROVIDES ADEQUATE SURVIVAL.

EHA Library, Michael Dickinson, 385516

ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB WHEN USED IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH PD-1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Alex F. Herrera, 385517

UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI–PD-1 TREATMENT

EHA Library, Peter Borchmann, 385518

GONADAL FUNCTION AND FERTILITY PRESERVATION IN PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA TREATED ACCORDING TO THE EURONET-PHL-C2 PROTOCOL: THE FERTILITY ADD-ON STUDY

EHA Library, Katja Drechsel, 385519

DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE

EHA Library, Paolo Corradini, 385520

COMBINATION OF PD-1 INHIBITION WITH IMMUNOMODULATORY DRUG TREATMENT IN HODGKIN AND LARGE B-CELL LYMPHOMA: RESULTS FROM A PHASE I/II STUDY

EHA Library, David Bond, 385521

SIGNIFICANT PREDICTORS OF DECREASED BONE MINERAL DENSITY IN PATIENTS WITH HODGKIN'S LYMPHOMA

EHA Library, Mariya Voytko, 385522

A NEW SCORING SYSTEM TO PREDICT SURVIVAL IN ELDERLY ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: STUDY BY TURKISH SOCIETY OF HAEMATOLOGY LYMPHOMA ACADEMY WORKING GROUP

EHA Library, Özgür Mehtap, 385523

PROGNOSIS ANALYSIS AND A NEW RISK MODEL FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED BY ANTI-PD-1: A REAL-WORLD MULTICENTER RETROSPECTIVE STUDY OF PATIENTS IN CHINA

EHA Library, Wenyan Yu, 385524

ADVANCED-STAGE CHL INTERNATIONAL PROGNOSTICATION INDEX: EXTERNAL VALIDATION IN A SINGLE-CENTER RETROSPECTIVE PATIENT DATASET AND COMPARISON TO THE HASENCLEVER IPS

EHA Library, Alessandro Cellini, 385525

PREVALENCE OF SOMATIC GENETIC MUTATIONS IN HRS CELLS OF HODGKIN LYMPHOMA PATIENTS FROM EASTERN MEDITERRANEAN, ASSESSED WITH, CIRCULATING TUMOR DNA, DIFFERS FROM THAT FOUND IN EUROPEAN COHORTS

EHA Library, Eldad Dann, 385526

RISK OF IMPAIRED OVARIAN RESERVE AND ADVERSE PREGNANCY OUTCOMES AFTER TREATMENT FOR CHILDHOOD HODGKIN LYMPHOMA; THE DCOG LATER-VEVO STUDY.

EHA Library, Katja Drechsel, 385527

MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY

EHA Library, Laurie Sehn, 385528

VERY LONG-TERM FOLLOW-UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.

EHA Library, clementine sarkozy, 385529

ZANUBRUTINIB PLUS OBINUTUZUMAB VERSUS OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED ANALYSIS OF THE ROSEWOOD STUDY

EHA Library, Judith Trotman, 385530

A MULTICENTER OBSERVATIONAL STUDY ON CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR LARGE B-CELL (LBCL) AND MANTLE CELL (MCL) LYMPHOMAS: THE ITALIAN CART-SIE REAL LIFE EXPERIENCE

EHA Library, Annalisa Chiappella, 385531

RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA

EHA Library, Nirav N Shah, 385532

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

EHA Library, Michał Taszner, 385533

LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL

EHA Library, Stephen Opat, 385534

HISTOLOGICAL TRANSFORMATION OF FOLLICULAR LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA WITHIN 48 MONTHS (TOD48) INDICATING AN ADVERSE PROGNOSIS: EVIDENCE FROM TWO POPULATION-BASED COHORTS

EHA Library, Hong-Hui Huang, 385535

EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING IN JAPANESE PATIENTS WITH RELAPSED/REFRACTORY INDOLENT B-CELL NON-HODGKIN’S LYMPHOMA: PRIMARY ANALYSIS OF THE PHASE 2 STUDY MIRAGE

EHA Library, Takahiro Kumode, 385536

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEIVED PIRTOBRUTINIB WITH AND WITHOUT ANTITHROMBOTIC AGENTS

EHA Library, Nicole Lamanna, 385538

ZANUBRUTINIB-RITUXIMAB CHEMO-FREE THERAPY WITH OR WITHOUT AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MANTLE CELL LYMPHOMA

EHA Library, Chang-Ju Qu, 385539

LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.

EHA Library, Benoit Tessoulin, 385540

CLINICAL IMPLICATIONS OF T CELL SUBSET COMPOSITION DURING MAINTENANCE THERAPY  AFTER FIRST-LINE IMMUNOCHEMOTHERAPY CONTAINING BENDAMUSTINE IN PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Rosalia Malafronte, 385541

A PHASE II INVESTIGATOR INITIATED STUDY OF ACALABRUTINIB, LENALIDOMIDE AND RITUXIMAB (AR2) IN PATIENTS WITH PREVIOUSLY UNTREATED HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA

EHA Library, Paolo Strati, 385542

MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF ZANUBRUTINIB (ZANU) VERSUS IBRUTINIB (IBRU) IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)

EHA Library, Catherine Thieblemont, 385543

COVID-19 VACCINE RESPONSES IN FOLLICULAR LYMPHOMA: DETERMINANTS OF HUMORAL AND CELLULAR IMMUNITY IN THE PETREA TRIAL OF FRONTLINE CHEMOIMMUNOTHERAPY

EHA Library, Yeong Lim, 385545

TREATMENT OF HEPATITIS C-ASSOCIATED MARGINAL ZONE LYMPHOMA(HCV+LMZ) WITH DIRECT-ACTING ANTIVIRAL DRUGS (DAAS)

EHA Library, sergey lepkov, 385546

CD20 CAR-T THERAPY WITH MB-106 FOR BTK INHIBITOR-REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (WM)/ LYMPHOPLASMACYTIC LYMPHOMA (LPL) – SINGLE INSTITUTION STUDY

EHA Library, Mazyar Shadman, 385547

A PHASE II, OPEN-LABEL, MULTICENTER STUDY OF CAPIVASERTIB, A POTENT, ORAL PAN-AKT INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (CAPITAL)

EHA Library, Daniel Hodson, 385548

A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY

EHA Library, Wei-Li Zhao, 385549

PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA.

EHA Library, Ana Jiménez Ubieto, 385550

A PROSPECTIVE TRIAL OF A NOVEL RECOMBINANT HUMANIZEDANTI-INTERLEUKIN-6 RECEPTOR MONOCLONAL ANTIBODY INJECTION(VDJ001) IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: THE PRELIMINARY RESULTS

EHA Library, Lu Zhang, 385551

IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY

EHA Library, Rohan Shotton, 385552

OBINUTUZUMAB INDUCTION AND MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINAEMIA

EHA Library, Tomasz Wróbel, 385553

THE PROGNOSTIC ROLE OF DEPTH OF RESPONSE DEPENDS ON THE TIME OF ASSESSMENT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY IN PATIENTS WITH SYMPTOMATIC WALDENSTROM MACROGOBULINEMIA (WM).

EHA Library, Lydia Montes, 385554

NEUROLOGIC INVOLVEMENT IN ADULTS WITH ROSAI-DORFMAN DISEASE: CLINICAL PRESENTATION AND OUTCOMES

EHA Library, Aldo Acosta Medina, 385555

CLINICAL OUTCOME OF PATIENTS WITH LOCALIZED PRIMARY GASTRIC MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: LONG-TERM FOLLOW-UP RESULTS FROM A SINGLE-INSTITUTION OBSERVATIONAL STUDY.

EHA Library, Kei Hirano, 385556

ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Andrew J. Davies, 385557

EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY

EHA Library, Lydia Scarfò, 385558

EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.

EHA Library, Erika Morsia, 385559

REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)

EHA Library, Bijal D. Shah, 385560

WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (≥75-YEAR-OLD): DESCRIPTION OF CLINICAL  FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN  ACADEMIC CENTER

EHA Library, Nicolò Danesin, 385561

PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STUDY

EHA Library, Nalin Payakachat, 385562

COMPARATIVE EFFICACY OF ZANUBRUTINIB (ZANU) VERSUS RITUXIMAB (RTX) IN RELAPSED MARGINAL ZONE LYMPHOMA (MZL): MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Catherine Thieblemont, 385563

HIGHLY SELECTIVE ALLOSTERIC MODULATOR OF THE PHOSPHOINOSITIDE 3-KINASE DELTA (PI3KΔ) ROGINOLISIB (IOA-244) IN A DOSE ESCALATION STUDY OF PATIENTS WITH REFRACTORY/RELAPSED FOLLICULAR LYMPHOMA (FL)

EHA Library, Carmelo Carlo-Stella, 385564

ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE 2 STUDY ELM-2

EHA Library, Jan Walewski, 385565

HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

EHA Library, Michael Roost Clausen, 385566

GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY

EHA Library, Adrian Minson, 385567

LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Wojciech Jurczak, 385568

CAMRELIZUMAB PLUS LOW-DOSE APATINIB AND PEGASPARGASE FOLLOWED BY RADIOTHERAPY FOR NEWLY DIAGNOSED STAGE I/II NATURAL KILLER/T-CELL LYMPHOMA: A PROSPECTIVE MULTICENTER SINGLE-ARM STUDY

EHA Library, Zhi-Ming Li, 385569

NOVEL TARGETED AGENTS IN COMBINATION WITH R-ICE (R-ICE-X) BASED ON GENOTYPING IN RELAPSED/REFRACTORY DLBCL.

EHA Library, Li Wang, 385570

POSITRON EMISSION TOMOGRAPHY FOR FINAL RESPONSE ASSESSMENT TO RITUXIMAB-DOSE ADJUSTED EPOCH IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: WHO IS WORTHY TO BE IRRADIATED?

EHA Library, Theodoros Vassilakopoulos, 385571

A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA

EHA Library, Stefan Habringer, 385572

EARLY CTDNA CLEARANCE AFTER CAR T-CELL INFUSION PREDICTS OUTCOME IN PATIENTS WITH LARGE B-CELL LYMPHOMA : RESULTS FROM ALYCANTE, A PHASE 2 LYSA STUDY

EHA Library, Marie-Helene DELFAU-LARUE, 385573

DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY

EHA Library, Eric Jacobsen, 385574

DURABLES RESPONSES ACHIEVED WITH ANTI-CD19 ALLOGENEIC CAR T ALLO-501/501A IN PHASE 1 TRIALS OF AUTOLOGOUS CAR T-NAÏVE PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)

EHA Library, Javier Munoz, 385575

PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL)

EHA Library, Paolo Strati, 385576

FINAL ANALYSIS OF AUSTRALASIAN LEUKAEMIA & LYMPHOMA GROUP NHL29: A PHASE II STUDY OF IBRUTINIB, RITUXIMAB AND MINI-CHOP IN VERY ELDERLY PATIENTS WITH NEWLY DIAGNOSED DLBCL

EHA Library, Emma Verner, 385577

EVALUATION OF STANDARD OF CARE IN SECOND-LINE FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE PRE-CAR-T ERA: A DUTCH POPULATION-BASED STUDY

EHA Library, Elise R.A. Pennings, 385578

FRONTLINE BRENTUXIMAB VEDOTIN AND CHP (A+CHP) IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA WITH LESS THAN 10% CD30 EXPRESSION: INITIAL SAFETY AND EFFICACY RESULTS FROM THE PHASE 2 STUDY SGN35-032

EHA Library, Swaminathan Iyer, 385580

SERUM TRIGLYCERIDE AND APOLIPOPROTEIN A1 AS BIOMARKERS FOR EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (ENKTL): A MULTICENTER STUDY

EHA Library, Qingqing Cai, 385581

LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Paolo F Caimi, 385582

CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL

EHA Library, Jinhua Liang, 385583

BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABATAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

EHA Library, Nirav Shah, 385584

EFFECT OF GLUCARPIDASE RESCUE IN PATIENTS WITH HIGH-DOSE METHOTREXATE INDUCED ACUTE KIDNEY INJURY: A FRENCH PHARMACOVIGILANCE DATABASE STUDY

EHA Library, Sabrina Pierre, 385585

FIRST INTERIM ANALYSIS OF A PHASE 1 STUDY OF ZANUBRUTINIB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Huilai Zhang, 385586